Search
Now showing items 1-1 of 1
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
(TAYLOR & FRANCIS LTD, 2022-01-02)
INTRODUCTION: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations ...